Our T2 Magnetic Resonance (T2MR) technology platform can detect pathogens, biomarkers, and other abnormalities in a broad range of unpurified sample types, including whole blood, plasma, serum, saliva, sputum, and urine. With limits of detection as low as 1 CFU/mL, T2MR has the potential for numerous additional applications beyond our current pipeline. T2 Biosystems is selectively seeking research partnerships and establishing alliances with dynamic organizations that have the capability and desire to develop additional breakthrough applications utilizing our T2MR platform.
T2 Biosystems is selectively seeking research partnerships and opportunities for co-development and commercialization include our current products as well as potential new applications for T2MR, ranging from companion diagnostics to research as well as non-healthcare applications.
We continue to pursue a strategic partnership for the commercial development of the T2Lyme™ Panel as an LDT.